LLY

As of 1 p.m. ET, the S&P 500 (SNPINDEX:^GSPC) rose 0.49% to 7,557.17, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 0.65% to 26,847.19 on tech strength, while the Dow Jones Industrial Average (DJINDICES:^DJI) slipped 0.01% to 50,641.15, lagging growth benchmarks but holding near record territory. Snowflake surged after blowout Q1 earnings and a $6 billion deal with Amazon, while Microsoft advanced on plans to deploy in-house coding AI models. In healthcare, Eli Lilly gained as CVS restored coverage for the obesity drug Zepbound, and France became the first EU country to cover weight loss drugs in certain cases. Snowflake is today’s headlining stock, rising 38% after reporting Q1 earnings after earnings yesterday. The cloud-based data platform provider grew sales by 33%, agreed to a $6 billion deal with Amazon, and now counts 813 of the Forbes Global 2000 as customers. The AI boom remains a major tailwind for the company. Elsewhere, it was a good day for many consumer-facing stocks. Dollar Tree, Best Buy, and Hormel are up 19%, 18%, and 13%, respectively, today after each stock reported earnings. I’d argue that these results are promising for the broader economy, especially after Walmart and Target's earnings last week showed that the U.S. consumer remains surprisingly resilient. The S&P 500’s biggest loser so far today is Synopsys, despite the semiconductor design company’s earnings beat and raised guidance. Investors shouldn’t panic over the company’s 9% decline today, especially considering the company has been a 9-bagger over the last decade. Before you buy stock in S&P 500 Index, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and S&P 500 Index wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,072!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,303,352!* Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individu...

Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.

Eli Lilly and Company (NYSE:LLY) is one of the best low risk stocks to buy in 2026. On May 21, Lilly’s Phase 3 TRIUMPH-1 trial evaluated retatrutide, an investigational once-weekly triple hormone receptor agonist (GIP/GLP-1/glucagon). The 80-week study involved 2,339 adults with obesity or overweight and at least one comorbidity, excluding diabetes. All doses met primary and secondary endpoints, showing significant weight loss and improvements in cardiometabolic markers like cholesterol and blood pressure. At 80 weeks, participants on the 12 mg dose lost an average of 70.3 lbs (28.3%), with 45.3% losing 30% or more. A 104-week extension for those with a BMI ≥ 35 showed the 12 mg dose reached an average loss of 85.0 lbs (30.3%). The 9 mg and 4 mg doses yielded average 80-week weight losses of 25.9% and 19.0%, respectively. Adverse events were consistent with incretin therapies, primarily causing nausea, diarrhea, constipation, and vomiting. Mild-to-moderate dysesthesia and urinary tract infections were also reported. Discontinuation rates due to side effects were 4.1% for 4 mg, 6.9% for 9 mg, and 11.3% for 12 mg, compared to 4.9% for the placebo. Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

With pharma and medtech Q1 earnings season now at a close, some sector areas performed better than others. In this episode, Robert Barrie, editor for Pharmaceutical Technology, and Ross Law, reporter at Medical Device Network, discuss the key trends from the quarter. In pharma, weight loss therapies and patent expirations dominated bottom lines. Eli Lilly's Mounjaro (tirzepatide) became the top-selling drug in the quarter, ousting MSD's Keytruda (pembrolizumab) in a changing of the guard. Meanwhile, the looming patent cliff is placing emphasis on late-stage pipelines and dealmaking activity for many companies. In medtech, geopolitical pressures meant some companies chose to revise their 2026 outlook. Trade through the Strait of Hormuz, one of the world’s most critical maritime chokepoints, has ongoing disruption, meaning the shipping of goods is currently more expensive. You can listen to the episode here: https://open.spotify.com/episode/30ko8xqvsSRLoyvwxWDTwM?si=3c2e38ebe6cc4d46 Eli Lilly, Novartis, GE HealthCare, and Stryker, amongst others, are covered. "Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trends" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

With pharma and medtech Q1 earnings season now at a close, some sector areas performed better than others. In this episode, Robert Barrie, editor for Pharmaceutical Technology, and Ross Law, reporter at Medical Device Network, discuss the key trends from the quarter. In pharma, weight loss therapies and patent expirations dominated bottom lines. Eli Lilly's Mounjaro (tirzepatide) became the top-selling drug in the quarter, ousting MSD's Keytruda (pembrolizumab) in a changing of the guard. Meanwhile, the looming patent cliff is placing emphasis on late-stage pipelines and dealmaking activity for many companies. In medtech, geopolitical pressures meant some companies chose to revise their 2026 outlook. Trade through the Strait of Hormuz, one of the world’s most critical maritime chokepoints, has ongoing disruption, meaning the shipping of goods is currently more expensive. You can listen to the episode here: https://open.spotify.com/episode/30ko8xqvsSRLoyvwxWDTwM?si=3c2e38ebe6cc4d46 Eli Lilly, Novartis, GE HealthCare, and Stryker, amongst others, are covered. "Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trends" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Dell Technologies' (DELL) AI Factory added 1,00 customers in the past quarter, bringing the total to

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The race is on for the next big thing in weight loss drugs and readouts from some of the top contenders are slated to drop this year. This rising crop of next-generation candidates aims not only to build on the waist-whittling results of earlier drugs but to make them more palatable for patients by reducing side effects, adjusting dosing and addressing weight loss plateaus. Novo Nordisk and Eli Lilly have already hit major milestones with the approval of GLP-1 pills, a more patient-friendly alternative to earlier injectable versions. Novo led the way with its Wegovy pill, approved in December 2025. A few months later, Lilly followed with Foundayo. The two new options are expected to compete for a growing share of the overall GLP-1 market, which is projected to reach $100 billion by 2030. As competition intensifies, the three companies below are approaching key trial readouts in 2026 that could help determine which next-generation therapies may be best positioned to take their share of the marketplace. Eli Lilly, already the leader in the GLP-1 space, is taking a multi-pronged approach with retatrutide, which targets a trio of hormones: GLP-1, GIP and glucagon. The drug could help solidify Lilly’s market position if it performs as hoped in several phase 3 trials this year. With an estimated $28.8 billion net present value, retatrutide is also at the top of the pile of up-and-comers. Results released so far hint that retatrutide may beat current market leaders in its magnitude of weight loss. December results from the phase 3 Triumph-4 trial, which is testing the drug in people with obesity and knee osteoarthritis, showed that the high-dose group saw a 28.7% reduction in body weight, or an average loss of 71.2 pounds after 68 weeks. By comparison, one late-stage study for Lilly’s blockbuster drug tirzepatide, the active ingredient in Zepbound and Mounjaro, demonstrated 15% to 20% weight loss during a similar time frame. Retatrutide also reduced knee pain with more than 1 in 8 patients reporting that they were free from that issue at the end of the trial. Detailed results from this trial are expected at a scientific meeting this year, according to the company. Another phase 3 trial, Transcend-T2D-1, is testing retatrutide i...

Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks That Will Profit from AI. The company has recently introduced LillyPod, the pharmaceutical industry’s most powerful NVIDIA-powered supercomputer. Embedded with AI, Lillypod is part of a continuous learning system that accelerates drug discovery and development. On May 12, 2026, Eli Lilly and Company (NYSE:LLY) announced late-phase trial results showing that Foundayo (orforglipron) and lower-dose Zepbound effectively maintain weight loss after patients switch from higher-dose injectables. The company’s ATTAIN-MAINTAIN study indicated that patients transitioning from Wegovy or Zepbound to oral Foundayo maintained most of their initial weight loss after one year. Similarly, the SURMOUNT-MAINTAIN trial showed that reducing Zepbound to 5 mg or continuing at the maximum tolerated dose will result in durable long-term weight maintenance. These findings were published in The Lancet and Nature Medicine and point to new flexible options for chronic obesity management while minimizing weight regain during the transition from one treatment to another. Previously, on May 6, 2026, Eli Lilly and Company (NYSE:LLY) announced an additional $4.5 billion investment in its Indiana manufacturing sites. This brings the company’s total state commitment to $21 billion since 2020. With this additional commitment, the company intends to support its evolving pipeline and anticipated demand for its medicines. Eli Lilly and Company (NYSE:LLY) also opened its first dedicated genetic medicine facility to support advanced therapies from research to commercial supply. Eli Lilly and Company (NYSE:LLY) is a healthcare company with headquarters in Indiana. Founded in 1876, the company develops human pharmaceutical products across cardiometabolic health, oncology, and immunology. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and 10 Best Battery Technology Stocks to Buy Now Disclosure: None. Follow Insider Monkey on Google News.

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly (LLY) stock is back in focus after the company reported a very strong Q1, raised its full year revenue and earnings guidance, and released new obesity trial data on Foundayo and Zepbound. See our latest analysis for Eli Lilly. The recent obesity trial updates, expanded manufacturing plans and steady flow of product news have kept Eli Lilly in the spotlight. A 30 day share price return of 9.13% has helped the stock recover some ground after a year to date decline of 6.82%. The 1 year total shareholder return of 38.54% and very large 5 year total shareholder return of around 4.3x show that long term momentum remains strong even after a softer 90 day share price return. If obesity and cardiometabolic treatments are on your radar, this is also a good moment to look beyond a single stock and review 34 healthcare AI stocks. With revenue and earnings guidance raised, Q1 growth above 50%, fresh obesity data and a US$905.8b valuation, the key question now is simple: are you looking at an undervalued leader or a stock already pricing in years of future growth? According to a widely followed narrative, Eli Lilly's fair value of $1,189.18 sits comfortably above the last close of $1,006.70, which sets up a clear valuation gap for investors to consider. Read the complete narrative. Want to see how those growth and margin assumptions stack up over time? The key driver here is a bold revenue ramp paired with a rich future earnings multiple. Curious how those inputs connect to a fair value that sits well above today's price? The full story is in the detailed narrative. Result: Fair Value of $1,189.18 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on GLP-1 pricing and safety holding up, since high monthly costs or unexpected side effect concerns could quickly weaken the bullish case. Find out about the key risks to this Eli Lilly narrative. The user narrative leans on strong growth and a valuation gap, but the current P/E of 35.5x tells a tougher story. That multiple is well above the US Pharmaceuticals industry average of 15.1x and also ahead of the peer average of 23.3x. Even against an estimated fair ratio of 37.4x, the stock already sits close to what the market could move towards....

AbbVie’s ABBV immunology franchise remained the company’s biggest growth driver in the first quarter of 2026, which beat expectations for both earnings and sales. The stronger-than-expected sales of Rinvoq and Skyrizi not only offset the continued erosion of legacy blockbuster Humira but also reinforced their importance as AbbVie’s key long-term growth drivers. Skyrizi sales increased 29.2% year over year to $4.48 billion, while Rinvoq generated $2.12 billion, up 20.2%. These upticks were fueled by strong volume growth and continued market share gains across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). During the first-quarter earnings call, management highlighted that Skyrizi continues to gain share in psoriatic disease and remains a leader in the frontline in-play patient share across both dermatology and rheumatology settings. The company also pointed to strong physician adoption in frontline inflammatory bowel disease (IBD) treatment settings, an important indicator of long-term market positioning. Regarding Rinvoq, AbbVie stated that demand remained strong across rheumatology, gastroenterology and dermatology markets, while highlighting improving prescription trends in ulcerative colitis following expanded label access supporting earlier-line use in IBD patients. Management’s confidence in the immunology franchise was reflected in updated 2026 guidance. AbbVie raised its sales expectations for both Skyrizi and Rinvoq by $100 million each. The company now expects Skyrizi revenues of approximately $21.6 billion and Rinvoq revenues of roughly $10.2 billion in 2026. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026. Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs’ growth. Rinvoq could be approved for two indications — vitiligo and alopecia areata — in 2026/early 2027. In addition, phase III data on Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected later this year. AbbVie believes that the next wave of potential approvals for Rinvoq could add roughly $2 billion to the pr...

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 response and 50% reaching remission at a median follow up of six months,” said Ben Capoccia, Director of Translation Medicine and Clinical Research at Imviva Biotech. READ MORE Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment Never Miss our Weekly Highlights HERE Contact: Exec Edge [email protected] Click HERE to follow us on LinkedIn

Nektar Therapeutics NKTR reported a loss of $1.82 per share for the first quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.74. In the year-ago quarter, the company had reported a loss of $3.62 cents per share. Total revenues in the first quarter came in at $10.9 million, up 3.8% year over year. The reported figure, however, slightly missed the Zacks Consensus Estimate of $11 million. Nektar sold its Huntsville manufacturing facility in December 2024, following which the company no longer records product revenues and lower non-cash royalty revenues. Nektar’s top line currently comprises non-cash royalty revenues. Year to date, shares of Nektar have rallied 97.2% compared with the industry’s rise of 1%. Image Source: Zacks Investment Research In the first quarter, research and development (R&D) expenses were $35.7 million, up 17% year over year, reflecting higher costs for developing its pipeline candidate, rezpegaldesleukin (rezpeg). General and administrative (G&A) expenses decreased 45% year over year to $13.4 million in the reported quarter, owing to lower legal expenses. As of March 31, 2026, Nektar had cash and cash equivalents and marketable securities worth $731.6 million compared with $245.8 million as of Dec. 31, 2025. Nektar's lead pipeline candidate (rezpeg) is being developed as a self-administered injection for several autoimmune and inflammatory diseases. Rezpeg selectively activates regulatory T-cells to calm the immune system and reduce inflammation. Two separate phase IIb studies are evaluating rezpeg for treating atopic dermatitis (REZOLVE-AD study) and alopecia areata (REZOLVE-AA study). Data from the REZOLVE-AD study announced in June 2025 showed that rezpeg significantly improved EASI scores versus placebo across all dose levels at week 16. Management believes the rapid reduction in EASI scores and improvements in itch support rezpeg’s potential as a first- and best-in-class immune modulator for atopic dermatitis. The company plans to initiate the phase III ZENITH-AD study on rezpeg for treating moderate-to-severe atopic dermatitis (also known as eczema) by July 2026. Last month, Nektar announced new data from a blinded 16-week treatment extension period of its phase IIb REZOLVE-AA study, evaluating rezpeg in patients with severe-to-very-severe alopecia areata. The 52-week top-line data from the 16-week blinded tre...